8-K current report · filed Oct 28, 2026

Replimune Group, Inc. (REPL) 8-K Current Report: October 28, 2026

Item 2.02Item EX-99.1REPL overview

Short answer

Replimune Group, Inc. (REPL) filed an 8-K current report with the SEC on October 28, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 fiscal 2026 results for quarter ended September 30, 2026 announced October 28, 2026.

Replimune Group, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 fiscal 2026 results for quarter ended September 30, 2026 announced October 28, 2026
  • Corporate updates included alongside financial results
  • Detailed figures and management commentary in Exhibit 99.1 press release

Item EX-99.1 · Exhibit EX-99.1

  • Fiscal Q2 2027 launch underway: TUDRIQEV delivered October 6, with more than 15 institutions prescribing
  • Commercial traction: Replimune engaged over 70% of its initial 200 priority accounts, with formulary placements emerging
  • Cash $307.8M versus $268.9M at March 31, 2026, supported by $141.0M equity proceeds and $15.0M debt draw
  • Q2 net loss $57.1M versus $83.1M prior year, while R&D declined to $34.4M from $57.9M
  • Key risk: accelerated approval depends on clinical benefit verification in the ongoing IGN YTE-3 Phase 3 trial

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Replimune Group, Inc. 8-K filings

Get the next REPL 8-K as it lands

Follow REPL for push alerts, or ask the research agent what this filing means.